Nohla
engages in the research and development of universal donor cellular therapies to treat patients with hematological malignancies... Read moreNohla
engages in the research and development of universal donor cellular therapies to treat patients with hematological malignancies... Read more
News
Nov 05, 2019
centralcharts
Press Release: Nohla : Notch Therapeutics - a new company with a revolutionary allogeneic ("off the shelf") T cell technology
Oct 12, 2018
BioPortfolio
Nohla Therapeutics: Nohla Therapeutics Inc Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 13082018 Prices from USD $250
Aug 06, 2018
PharmiWeb
Nohla Therapeutics: Nohla Therapeutics Receives FDA Fast Track Designation for Dilanubicel for Allogeneic Cord Blood Transplant Patients
Jul 31, 2018
BioPortfolio
Nohla Therapeutics: Nohla Therapeutics Inc Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 23042018 Prices from USD $250
Jul 23, 2018
The Business Journals: Seattle
Nohla Therapeutics: Nohla Thearaputics
Jul 12, 2018
GeekWire
Nohla Therapeutics: Nohla Therapeutics raises another $11M to support leukemia treatment trials
Jul 12, 2018
The Business Journals: Seattle
Nohla Therapeutics: Nohla adds $11 million in funding and three new investors
Jul 12, 2018
FinSMEs
Nohla Therapeutics: Nohla Therapeutics Raises Additional $11M in Second Close of $56M Series B
Jun 15, 2018
PharmiWeb
Nohla Therapeutics: Nohla Announces Presentation of Dilanubicel (NLA101) Data at EHA Annual Meeting Showcasing Excellent Long-term Survival Outcomes
Jun 06, 2018
PharmiWeb
Nohla Therapeutics: Nohla Receives EMA PRIME Designation for Dilanubicel (NLA101) to Treat Hematopoietic Stem Cell Transplant Patients
Nohla Competitors
1
2
3
4
5
6
7
8
9
10